Voluntary Drug Poisoning by Psychoactive Molecules: Identify Cognitive Markers (IMG-COG)

Toulouse University Hospital

Status: Unknown

Conditions: Drug Poisoning; Suicide

Treatments: Behavioral: Two visits for evaluation

Study type: Interventional

Funder types: Other

Identifiers

NCT03481192

RC31/17/0160

2017-A01581-52 (Other Identifier)

Details and patient eligibility

About

To identify in patients admitted for Voluntary drug poisoning (IMV) by psychoactive substances, T1 predictors of T2 recall of psychiatric interview and care project.

Full description

The methodology will compare the episodic memory results of patients admitted for IMV who have exclusively ingested amnesic substances to a subject control group that has made IMV with non-amnesic substances such as paracetamol. The purpose of this comparison is to ensure that memory problems are not related to the context of the suicidal crisis.

The second step will be able to relate the memory score of the predictor variables. To achieve this, it will perform a multivariate linear regression in each group in order to confirm the results of the pilot study and to be able to regress in the control group which was not possible in the pilot study because of the lack of effective.

Finally, this study will try to establish, using Receiver Operating Characteristic (ROC) curves, thresholds for cognitive scores and begin to develop a tool for clinical practice.

Enrollment: 103 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Group amnesic substances :

• Age from 18 to 65 years
• Admitted to emergencies for IMV by benzodiazepines
• Supported at Toulouse University Hospital (hospitalization, outpatient)

Group control :

• Age from 18 to 65 years
• Admitted to emergencies for IMV by non-depressive substances of the central nervous system
• Supported at Toulouse University Hospital (hospitalization, outpatient)

Exclusion criteria

• Cognitive Disorder Due to an Organic Disorder Neuro Degenerative Disease, Korsakoff Syndrome) or Mental Retardation Diagnosed
• Patient under guardianship
• Not speaking and / or not reading French
• Neurodegenerative disease diagnosed

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

103 participants in 2 patient groups

A group using amnesic substances

Experimental group

Description:

A group of patients admitted for IMV exclusively using amnesic substances. Benzodiazepines, benzodiazepines, tricyclic antidepressants, neuroleptics, antihistamines, other atropine substances, anti-epileptics and opiates. Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.

Treatment:

Behavioral: Two visits for evaluation

A control group

Active Comparator group

Description:

A control group that ingested exclusively non-amnesic substances among them most frequently ingested in this context, ie the following classes: level 1 analgesics, antibiotics, serotonergic and noradrenergic antidepressants, oral antidiabetic, thyroid hormones, anti oral coagulant. Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.

Treatment:

Behavioral: Two visits for evaluation